LG Chem's First Anti-Cancer Compound Enters U.S. Phase 1 Trial

LG Chem, in collaboration with AVEO Oncology, has initiated a pioneering clinical trial in the United States. The trial involves LB-LR1109, LG Chem's first proprietary anti-cancer investigational drug. This Phase 1 study is designed to determine the appropriate dosage for further research and to assess the drug's safety, tolerability, preliminary efficacy, and various pharmacological properties. The trial will involve patients with several types of advanced cancers, including non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, and malignant melanoma, who have not responded to standard treatments.

In preclinical studies, LB-LR1109 demonstrated promising dose-dependent anti-cancer effects. Consequently, LG Chem secured approval for an Investigational New Drug application from the U.S. Food and Drug Administration (FDA) in December of the previous year.

The drug targets a protein known as Leukocyte Immunoglobulin Like Receptor B-1 (LILRB1), which is emitted by cancer cells to evade immune attacks. LILRB1 is found on the surfaces of various immune cells, including T cells, natural killer (NK) cells, and macrophages. The mechanism of LB-LR1109 is believed to activate these immune cells simultaneously, potentially offering a broader anti-cancer effect compared to therapies that target only a single type of immune cell.

Dr. Alex Spira, Director of Next Oncology at Virginia Cancer Specialists Research Institute, expressed enthusiasm about the partnership with LG Chem. He highlighted the significant unmet need for patients who have exhausted standard treatment options, emphasizing the potential of novel immune checkpoint inhibitors like LB-LR1109.

Jeewoong Son, MD, President of LG Chem Life Sciences Company, reiterated the company's commitment to developing innovative cancer treatments. He noted that while LB-LR1109 is LG Chem's first oncology compound, the company is building a robust pipeline targeting novel oncology targets. Their goal is to provide differentiated treatment options in oncology, addressing areas with the greatest unmet medical need.

The progression of this program into clinical testing marks a significant step for both LG Chem and AVEO Oncology. It brings them closer to their shared vision of becoming a leading global oncology company with a strong portfolio of innovative therapies.

AVEO Oncology, a subsidiary of LG Chem, focuses on developing and commercializing cancer treatments. The company already markets FOTIVDA® (tivozanib) in the United States for patients with relapsed or refractory renal cell carcinoma who have undergone multiple prior treatments. AVEO continues to explore new combinations of FOTIVDA in immuno-oncology and other targeted therapies. The company became a part of LG Chem Life Sciences USA, Inc. in January 2023 but continues to operate under the AVEO Oncology brand.

LG Chem, a global chemical leader, operates across various sectors including petrochemicals, advanced materials, and life sciences. The company produces a wide range of high-value products, from petrochemicals to renewable plastics, and specializes in cutting-edge electronic and battery materials. LG Chem Life Sciences focuses on developing, manufacturing, and globally commercializing pharmaceutical products, particularly in Oncology, Immunology, and Metabolic diseases. Their mission is to transform lives through innovative science and leading-edge solutions.